Table 1.
Clinicopathologic variables of patients with lymph node metastases: comparison of patients with (HALN+) and without (HALN−) hepatic artery lymph node (HALN) metastatic disease
| HALN– (n = 156) | HALN+ (n = 41) | P-value | ||
|---|---|---|---|---|
| Lymph nodes retrieved, median (range) | 21 (5–58) | 20 (5–41) | 0.290 | |
| Lymph nodes positive, median (range) | 3 (1–24) | 6 (1–22) | 0.012 | |
| Lymph node ratio, median (range) | 0.14 (0.02–0.90) | 0.20 (0.30–0.57 | 0.001 | |
| Size of metastasis, mm, median (range) | 11 (2–26) | 13 (3–25) | NA | |
| Tumour stage, n (%) | T1 | 3 (2.4%) | 0 | 0.528 |
| T2 | 7 (5.7%) | 3 (9.1%) | ||
| T3 | 113 (91.9%) | 30 (90.9%) | ||
| Differentiation, n (%) | Good | 11 (7.4%) | 3 (7.3%) | 0.470 |
| Moderate | 71 (47.7%) | 17 (41.5%) | ||
| Poor | 21 (14.1%) | 10 (24.4%) | ||
| Perineural invasion, n (%) | 85 (77.3%) | 27 (87.1%) | 0.317 | |
| Lymphovascular invasion, n (%) | 62 (57.4%) | 26 (81.3%) | 0.021a | |
| Vascular invasion, n (%) | 10 (6.7%) | 5 (12.2%) | 0.323 | |
| Positive margin, n (%) | 21 (14.1%) | 8 (19.5%) | 0.462 | |
| Adjuvant chemotherapy, n (%) | 56 (60.8%) | 17 (56.6%) | 0.160 | |
a
Significant at P ≤ 0.05.
NA, not applicable.